TOP TALENT FROM DIVERSE BACKGROUNDS
BOARD OF DIRECTORS
CHAIRMAN OF THE BOARD, Taiho Oncology Europe GMBH
Atsushi joined Taiho Pharmaceutical Co., Ltd. in 1997 and was appointed Executive Director of the company in March 2021.
He has been involved in business development at Taiho Pharmaceutical for many years, building and maintaining alliances with other companies through a number of commercial transactions. Over the course of building these important alliances, he has always valued the pursuit of “drugs whose therapeutic effects make them truly meaningful” – the kind of drugs that bring smiles to the faces of patients and their families, treatments that anyone would hope to have access to when a family member or friend is suffering from disease.
As Chairman of the Board of Taiho Oncology Europe GmbH, Atsushi is responsible for making decisions on management policies and developing strategies to advance the company’s interests in the European market. More immediately, Atsushi continues to look towards shaping the future of the organization and maintains a focus on guiding Taiho Oncology Europe GmbH efforts to build a sales/marketing organization, while cooperating with other group companies. Going forward, he hopes to contribute to health and smiles for patients throughout Europe by further expanding the pipeline of anti-cancer drugs and promoting their proper use.
Director, Taiho Oncology Europe GMBH
Michael is the current Senior Vice President, Chief Commercial Officer of the company’s US affiliate Taiho Oncology, Inc., having started at Taiho Oncology as Vice President, Sales and Marketing in 2013. He has been working in oncology since 1996, and began his career in the pharmaceutical and biotech industry at Abbott Pharmaceuticals. He has since had roles of increasing responsibility at Bristol-Myers Squibb Oncology, Pharmacia Oncology, Pharmacyclics, Amgen, ImClone Systems, and Allos Therapeutics. Michael has a proven track record of leadership that has consistently delivered excellent business and people development results. He earned his Bachelor of Arts from Villanova University. Mike was appointed to the company’s Board of Directors at its formation in 2020.
EUROPEAN LEADERSHIP TEAM
Taiho Oncology’s leadership team brings strong leadership to the European marketplace, while staying true to Taiho’s legacy of developing the highest quality pharmaceuticals that improve the lives of people everywhere.
Peter Foertig, MD
VICE PRESIDENT & HEAD OF MEDICAL AFFAIRS EUROPE
TAIHO ONCOLOGY EUROPE GMBH
Peter joined Taiho in March 2021 as Vice President and Head of Medical Affairs Taiho Oncology Europe GmbH. Peter has more than 20 years of experience in medical oncology, including having held positions in early and late stage development at Schering&Plough and Amgen. In addition, he held European and global roles in Medical Affairs at Baxalta, Shire and Tesaro Bio. Prior to joining Taiho, Peter was the Head of Medical Affairs Europe at Stemline Therapeutics.
Peter brings deep knowledge of the complexity of drug development and pan-EU regulations as well as commercialization, launch and lifecycle management. He has a successful track record of enabling EMA approvals and overseeing multiple product launches and lifecycles across multiple countries/territories.
Peter received his Doctorate of Medicine from the Johann Wolfgang Goethe University, Frankfurt/Main, Germany.
SVP, GENERAL COUNSEL
TAIHO ONCOLOGY EUROPE GMBH
Chris currently serves as Taiho Oncology, Inc.’s Senior Vice President and General Counsel and is Taiho Oncology Europe GmbH point of contact for legal matters. Chris’ work in the legal department has assisted Taiho in transforming the legal function primarily from a development stage contracts department to its present structure of a fully capable legal function within the company as it continues to expand globally. Prior to joining Taiho Oncology, Chris represented both domestic and global public and private life science and pharmaceutical companies having worked both in-house and in the business and finance unit of a large international firm. He holds each of a Bachelor of Arts from Wake Forest University, a Juris Doctorate from the Villanova University School of Law, and a Masters of Business Administration from the Villanova University College of Commerce and Finance.